跨鼻息肉亚型的生物疗法。
Biologic Therapies across Nasal Polyp Subtypes.
作者信息
Bolk Kody G, Wise Sarah K
机构信息
Department of Otolaryngology-Head and Neck Surgery, Emory University Hospital Midtown, Emory University, Atlanta, GA 30308, USA.
出版信息
J Pers Med. 2024 Apr 19;14(4):432. doi: 10.3390/jpm14040432.
Abstract
Chronic rhinosinusitis with nasal polyposis is a common inflammatory condition, with subtypes like aspirin-exacerbated respiratory disease, allergic fungal rhinosinusitis, and central compartment atopic disease sharing a common type 2 inflammatory pathway. Respiratory biologic therapies have been developed that target type 2 inflammation. In this article, we discuss the use of respiratory biologic therapies for nasal polyposis in general, as well as within the various subtypes of nasal polyps. Further, we discuss future roles of novel biologic therapies targeting type 2 inflammation in nasal polyposis.
摘要
伴鼻息肉的慢性鼻-鼻窦炎是一种常见的炎症性疾病，其亚型如阿司匹林加重性呼吸道疾病、变应性真菌性鼻-鼻窦炎和中央区特应性疾病共享一条共同的2型炎症途径。已经开发出针对2型炎症的呼吸道生物疗法。在本文中，我们讨论呼吸道生物疗法在一般鼻息肉以及鼻息肉各种亚型中的应用。此外，我们还讨论了针对鼻息肉2型炎症的新型生物疗法的未来作用。
相似文献
1
Biologic Therapies across Nasal Polyp Subtypes.
J Pers Med. 2024 Apr 19;14(4):432. doi: 10.3390/jpm14040432.
2
Allergy and Asthma Prevalence and Management Across Nasal Polyp Subtypes.
Otolaryngol Clin North Am. 2024 Apr;57(2):253-263. doi: 10.1016/j.otc.2023.09.001. Epub 2023 Oct 10.
3
Central compartment atopic disease: outcomes compared with other subtypes of chronic rhinosinusitis with nasal polyps.
Int Forum Allergy Rhinol. 2021 Nov;11(11):1549-1556. doi: 10.1002/alr.22819. Epub 2021 Jun 2.
4
Aspirin-exacerbated respiratory disease and current treatment modalities.
Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1291-1300. doi: 10.1007/s00405-016-4273-1. Epub 2016 Aug 18.
5
Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Curr Allergy Asthma Rep. 2021 Jun 10;21(6):36. doi: 10.1007/s11882-021-01013-y.
6
Chronic rhinosinusitis.
J Allergy Clin Immunol Pract. 2013 May-Jun;1(3):205-11; quiz 212-3. doi: 10.1016/j.jaip.2012.12.001. Epub 2013 Feb 6.
7
Comprehensive Analysis of Nasal Polyps Reveals a More Pronounced Type 2 Transcriptomic Profile of Epithelial Cells and Mast Cells in Aspirin-Exacerbated Respiratory Disease.
Front Immunol. 2022 Mar 28;13:850494. doi: 10.3389/fimmu.2022.850494. eCollection 2022.
8
T cells in chronic rhinosinusitis with nasal polyposis.
Curr Opin Otolaryngol Head Neck Surg. 2010 Jun;18(3):200-5. doi: 10.1097/MOO.0b013e3283382082.
9
Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP).
Int Forum Allergy Rhinol. 2024 Mar;14(3):651-659. doi: 10.1002/alr.23246. Epub 2023 Aug 10.
10
IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.
J Allergy Clin Immunol. 2020 Jun;145(6):1574-1584. doi: 10.1016/j.jaci.2020.02.035. Epub 2020 Mar 19.
引用本文的文献
1
The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma.
Adv Respir Med. 2025 Jun 20;93(4):21. doi: 10.3390/arm93040021.
2
Rhinosinusitis: Evidence and experience - 2024.
Braz J Otorhinolaryngol. 2025 May 19;91(5):101595. doi: 10.1016/j.bjorl.2025.101595.
本文引用的文献
1
Ocular Surface Adverse Events are not Associated with Dupilumab use in Nasal Polyp Treatment.
Laryngoscope. 2024 Jun;134(6):2602-2608. doi: 10.1002/lary.31205. Epub 2023 Dec 1.
2
Successful Treatment of Eosinophilic Chronic Rhinosinusitis and Secretory Otitis Media in Refractory Asthma With Thymic Stromal Lymphopoietin (TSLP) Receptor Monoclonal Antibody.
Cureus. 2023 Oct 27;15(10):e47798. doi: 10.7759/cureus.47798. eCollection 2023 Oct.
3
Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.
Am J Otolaryngol. 2024 Jan-Feb;45(1):104106. doi: 10.1016/j.amjoto.2023.104106. Epub 2023 Nov 5.
4
Long-Term Efficacy of Dupilumab for Eosinophilic Chronic Rhinosinusitis.
Am J Rhinol Allergy. 2024 Jan;38(1):14-22. doi: 10.1177/19458924231204128. Epub 2023 Sep 26.
5
Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Int Forum Allergy Rhinol. 2024 Mar;14(3):668-678. doi: 10.1002/alr.23249. Epub 2023 Aug 22.
6
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis.
J Allergy Clin Immunol Pract. 2023 Dec;11(12):3650-3661.e3. doi: 10.1016/j.jaip.2023.07.024. Epub 2023 Jul 26.
7
Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months.
Allergy. 2023 Oct;78(10):2684-2697. doi: 10.1111/all.15796. Epub 2023 Jul 2.
8
Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy.
Int Forum Allergy Rhinol. 2024 Jan;14(1):96-109. doi: 10.1002/alr.23234. Epub 2023 Jul 18.
9
Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.
Int Forum Allergy Rhinol. 2024 Jan;14(1):18-31. doi: 10.1002/alr.23219. Epub 2023 Jul 18.
10
Inflammatory characteristics of central compartment atopic disease.
Int Forum Allergy Rhinol. 2023 Dec;13(12):2133-2143. doi: 10.1002/alr.23207. Epub 2023 Jul 1.
Zotero 插件